Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on Immix Biopharma and increased the price target to $8.00 from $7.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Robert Burns has given his Buy rating due to a combination of factors related to Immix Biopharma’s promising clinical trial results and financial outlook. The updated results from the NEXICART-2 trial, which will be presented at the upcoming ASH meeting, have shown significant efficacy in treating patients with relapsed/refractory AL amyloidosis. The trial demonstrated a 100% response rate and a 70% complete response rate, with no severe adverse events reported, highlighting the potential of NXC-201 as a treatment option where there are currently no FDA-approved therapies.
Additionally, despite reporting a net loss for the third quarter of 2025, Immix Biopharma has maintained a solid cash position, providing a financial runway into the second quarter of 2026. The anticipated data release at the ASH meeting could further strengthen the company’s position, potentially leading to an equity raise. These factors collectively support the Buy rating, reflecting confidence in the company’s strategic direction and potential for future growth.